[ 124 I]I-cobimetinib PET enables noninvasive tracking of MEK inhibition in MAPK-driven cancers
Radiochimica Acta · 24.06.2026 · 114 (6) · 433-447
DOI: 10.1515/ract-2025-0112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiochimica Acta, online erschienen am 21.04.2026. Verfasst von Faiza Amjad und 3 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
We report the synthesis, radiolabeling, and preclinical evaluation of [ 124 I]I-cobimetinib, a novel PET radiotracer for imaging MAPK pathway-driven tumors. Cobimetinib was converted to its boron pinacol ester (Bpin-cobimetinib) in 82 % yield, with >98 % purity confirmed by NMR, HRMS, and elemental analysis. Copper-mediated radioiodination of the Bpin precursor afforded [ 124 I]I-cobimetinib with >98 % radiochemical purity and 64 ± 8 % isolated radiochemical yields ( n = 6, range: 56–74 %) across multiple syntheses. The radiotracer showed high lipophilicity (logD = 3.4 ± 0.2) and excellent in vitro stability in PBS (90.1 ± 0.8 % intact at 72 h) and serum (81.2 ± 0.5 % intact at 72 h). In vitro , [ 124 I]I-cobimetinib displayed potent MEK-dependent cytotoxicity, with IC 50 values of 0.30 ± 0.08 μM in KRAS/BRAF-mutant lines versus 2.76 ± 0.55 μM in MAPK-low cells, and exhibited 2.5–4.5-fold higher cellular uptake in MAPK-driven models. In tumor-bearing mice, [ 124 I]I-cobimetinib rapidly accumulated in tumors (2.9 ± 0.48 %ID/g at 2 h, 6.4 ± 0.6 %ID/g at 48 h) with high tumor-to-blood (7.2) and tumor-to-muscle (14.9) ratios, while blocking studies confirmed MEK-specific uptake. Low thyroid uptakes (1.2–2.3 %ID/g over 96 h) indicated limited in vivo deiodination. PET/CT imaging showed intense tumor localization with minimal background, demonstrating robust in vivo retention (SUVmean = 3.8 ± 0.4; SUVmax = 5.6). These results establish [ 124 I]I-cobimetinib as a selective, stable PET tracer for noninvasive imaging of MEK-activated tumors, supporting its potential for tumor characterization and therapy monitoring in MAPK pathway driven cancers.
Zitieren
APA
Amjad, F., Shah, S. Q., Santos-Oliveira, R., & Ilem-Ozdemir, D. (2026). [ 124 I]I-cobimetinib PET enables noninvasive tracking of MEK inhibition in MAPK-driven cancers. Radiochimica Acta, 114(6), 433-447. https://doi.org/10.1515/ract-2025-0112
Vancouver
Amjad F, Shah SQ, Santos-Oliveira R, Ilem-Ozdemir D. [ 124 I]I-cobimetinib PET enables noninvasive tracking of MEK inhibition in MAPK-driven cancers. Radiochimica Acta. 2026;114(6):433-447. doi:10.1515/ract-2025-0112
BibTeX
@article{Amjad2026,
author = {Amjad, Faiza and Shah, Syed Qaiser and Santos-Oliveira, Ralph and Ilem-Ozdemir, Derya},
title = {[ 124 I]I-cobimetinib PET enables noninvasive tracking of MEK inhibition in MAPK-driven cancers},
journal = {Radiochimica Acta},
year = {2026},
volume = {114},
number = {6},
pages = {433--447},
doi = {10.1515/ract-2025-0112}
}
EUVIMED